Trial reportLeukemia2017
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01596114 (Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukemia After Stopping TKI), which is not on this map. Cited by 149 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukemia After Stopping TKI
Who cites it
149 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Trial
- KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study.Blood neoplasia · 2024Trial
- Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.Annals of hematology · 2023Trial
- Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.International journal of hematology · 2023Trial
- In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.Frontiers in immunology · 2023Trial
- Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.Haematologica · 2022Trial
- A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.Leukemia research · 2021Trial
- Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.Cancer science · 2020Trial
- Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).International journal of clinical oncology · 2019Trial
- Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.Haematologica · 2018Trial
- Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.International journal of hematology · 2018Trial
- Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.Cancer science · 2018Trial
- Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.Haematologica · 2017Trial
- Predictive biomarkers of sustained treatment-free remission in chronic myeloid leukemia: gene expression analyses from the ENESTfreedom and ENESTop studies.Haematologica · 2026Article
- Treatment-free remission and immune profiling after frontline second-generation TKI therapy in CML.Blood advances · 2026Article
- Treatment-Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure.Cancer science · 2026Review
- Review
- Article
- Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.International journal of hematology · 2026Observational
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies suggest that a proportion of chronic myeloid leukemia (CML) patients in deep molecular remission can discontinue the tyrosine kinase inhibitor (TKI) treatment without disease relapse. In this multi-center, prospective clinical trial (EURO-SKI, NCT01596114) we analyzed the function and phenotype of T and NK cells and their relation to successful TKI cessation. Lymphocyte subclasses were measured from 100 imatinib-treated patients at baseline and 1 month after the discontinuation, and functional characterization of NK and T cells was done from 45 patients. The proportion of NK cells was associated with the molecular relapse-free survival as patients with higher than median NK-cell percentage at the time of drug discontinuation had better probability to stay in remission. Similar association was not found with T or B cells or their subsets. In non-relapsing patients the NK-cell phenotype was mature, whereas patients with more naïve CD56
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.